Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE004 (DEU) (Dr. Tanaka)
· consented 2022-04-06
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: N
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 235); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: UNKNOWN; onset 2023-01-18 (study day 267); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-28 (study day 367); relationship: N; serious criteria: hospitalization
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.